Nosis Bio Announces New Strategic Collaboration and License Agreement with Johnson & Johnson to Revolutionize Delivery in Neurology
ALAMEDA, Calif. – Nosis Bio, a pioneer in AI-enabled cell-specific delivery for RNA medicines, today announced an expansion of its strategic collaboration with Johnson & Johnson.* Their initial collaboration has been expanded through an option exercise, and simultaneously, Nosis Bio and Johnson & Johnson have entered into a new strategic collaboration agreement focused on neurology.
This expansion represents a significant commitment to the Nosis Connexa™ platform, leveraging its proprietary AI-driven design capabilities to overcome the blood-brain barrier and enable precise delivery of therapeutics to critical, hard-to-reach cell types.
“Cell-specific delivery is the holy grail of modern medicine. This expanded partnership highlights confidence in our Connexa™ platform and our ability to precisely target cells within the central nervous system,” said Jim Martineau, Co-founder and CEO of Nosis Bio. “We are redefining what’s possible for patients with chronic disease.”
The collaborations will deploy Nosis’ Connexa™ platform, which combines a proprietary atlas of cell-specific internalizing receptor targets with physics-aware generative AI, to design delivery vehicles that can navigate complex cell types.
About Nosis Bio
Nosis Bio designs and develops cell-targeted RNA therapeutics, unleashing the full potential of precision medicines in the treatment of chronic disease. Nosis’ platform, Connexa™, combines a proprietary atlas of cell-specific internalizing receptor targets, physics-aware machine learning, generative AI drug design, and high throughput in vivo data characterization to rapidly advance cell-targeted RNA medicines into therapeutic development. Nosis Bio and Johnson & Johnson entered into their first agreement in December 2024. Nosis Bio is a venture-backed AI-enabled biopharma based in Alameda, CA, with a team of experts in deep learning, molecular design, in vivo pharmacology, and RNA therapeutic development.
*Legal entity: Janssen Biotech, Inc.
Media Contact: bd@nosisbio.com nosisbio.com